The world's first heat with thrombocytopenia syndrome inactivated vaccine approved for clinical use by China National Pharmaceutical Group.

Recently, the new type of vaccine for fever with thrombocytopenia syndrome developed by the National Key Laboratory for the Development of New Infectious Diseases Focused Laboratory of China National Pharmaceutical Group and the Virus Disease Prevention and Control Department of the Chinese Center for Disease Control and Prevention has received the clinical trial approval notification issued by the National Medical Products Administration. This innovative vaccine, a type 1.1 inactivated vaccine for fever with thrombocytopenia syndrome, relies on the technology platform of the National Key Laboratory for the Development of New Infectious Diseases, and through the innovative breakthroughs of the research team in strain selection, process development, quality system, and animal models, it has become the world's first similar product to be approved for entry into clinical trials.